서울특별시내과

The Liver Week 2026 Day 2

Name: The Liver Week 2026 Day 2
Start: 2026-06-12
End: 2026-06-12
Location: 콘래드 서울, Room 1AB, 1C, 2AB, 2C, 3, 4A~C

6점 일반 6

주최: 대한간학회
일자: 2026-06-12
장소: 콘래드 서울, Room 1AB, 1C, 2AB, 2C, 3, 4A~C
수강료: 210,000원

수강료 상세 안내

회원/비회원·전공의·사전/현장등록 등 상세 등록비는 KMA 신청 페이지에서 확인하세요.

평점 구성

총 평점6점

필수평점0점

일반평점6점

연수평점은 3년 24점·연 8점 상한·필수 2점 요건이 있습니다. 이 행사 들으면 올해 상한까지 몇 점? →

KMA 등록 페이지에서 신청 → 평점 계산기

세부 일정 (95강)

08:00~08:15 Expanding Indications for Surgery and Transplantation in Hepatic Malignancies: Ethics, Donor Considerations, and Future Perspectives Room 1AB 신동현(성균관의대)
08:15~08:30 Downstaging and Conversion to Resection or Transplantation for Advanced HCC Using Systemic and Locoregional Therapies Room 1AB 이윤빈(서울의대)
08:30~08:45 Surgical Management of Uncommon Hepatic Malignancies Room 1AB 김상진(고려의대)
08:45~09:00 Liver Transplantation for Uncommon Hepatic Malignancies: Beyond Current Criteria Room 1AB 김상훈(울산의대)
09:00~09:10 Discussion Room 1AB
09:10~09:30 Immunological Features of Chronic Hepatitis B: Stage-Independent Patterns of HBV-Specific T Cell Responses Room 1AB Nina Le Bert(Duke-NUS Medical School, Singapore)
09:30~09:50 Clarifying the Indeterminate Phase in Chronic Hepatitis B: Defining Its Natural Course and Virological Characteristics Room 1AB 김기애(경희의대)
09:50~10:10 Impact of Antiviral Therapy in the Indeterminate Phase of Chronic Hepatitis B: Who Should Be Treated Room 1AB Yao-Chun Hsu(I-Shou Univ., Taiwan)
10:10~10:30 Latest Updates on Novel Biomarkers for Chronic Hepatitis B Room 1AB Yasuhito Tanaka(Kumamoto Univ., Japan)
10:30~10:50 KASL Leading Research Achievement Award Room 1AB
10:50~11:10 Opening Ceremony Room 1AB
11:10~11:40 From Clinic to Policy: A Physician Room 1AB Chien-Jen Chen(Genomics Research Center, Taiwan)
11:40~11:55 Early Antiviral Therapy Reduces the Risk of Hepatocellular Carcinoma in Chronic Hepatitis B: Causal Evidence from a Multinational Regression Discontinuity Study Room 1AB 신현재(서울의대)
11:55~12:10 Sustained Enrichment of Butyrate- and Acetate-Producing Microbes Is Associated with Better Outcomes to Atezolizumab Plus Bevacizumab in Advanced Hepatocellular Carcinoma Room 1AB 이순규(가톨릭의대)
12:10~12:25 Tailored Surgical Approaches for Hepatocellular Carcinoma in Caudate Lobe Room 1AB 김상훈(울산의대)
12:25~12:40 Early Post-Transplant Recipient-Derived Cell-Free DNA Predicts One-Year Graft Survival in Liver Transplant Recipients Room 1AB 민은기(연세의대)
13:30~13:50 Public Health and Policy Implications in the Metabolic Era Room 1AB 손원(성균관의대)
13:50~14:10 Contemporary MASLD Management: Integrating Available Therapies, Metabolic Care, and Prevention of Sarcopenia Room 1AB 이혜원(연세의대)
14:10~14:30 Near-Future MASLD Therapies: Resmetirom, GLP-1 Receptor Agonists and Emerging Agents Room 1AB Kathleen E. Corey(Harvard Medical School, USA)
14:30~14:50 Rethinking HCC Surveillance in the MASLD Era: From Non-Cirrhotic Risk to Global Strategies Room 1AB Ju Dong Yang(Cedars-Sinai Medical Center, USA)
14:50~15:10 Expanding Indications for Nucleos(t)ide Analogue Therapy in Chronic Hepatitis B: Clinical Benefits and Long-Term Outcomes Room 1AB 신동현(성균관의대)
15:10~15:30 Personalizing Antiviral Therapy in Hepatitis B: Balancing Safety, Efficacy, and HCC Prevention Room 1AB Tung-Hung Su(National Taiwan Univ., Taiwan)
15:30~15:50 Discontinuation of Antiviral Therapy in Chronic Hepatitis B Room 1AB Yao-Chun Hsu(I-Shou Univ., Taiwan)
15:50~16:10 Immune Mechanisms Driving HBsAg Decrease with Various Anti-HBV Therapeutics Room 1AB Seng-Gee Lim(National Univ. of Singapore, Singapore)
16:20~16:40 Beyond Cure: Practical Care for Hepatitis C Patients with MASLD Room 1AB Takumi Kawaguchi(Kurume Univ., Japan)
16:40~17:00 The Need for Greater Awareness and an Evolving Treatment Landscape in Hepatitis D Infection Room 1AB 정영걸(고려의대)
17:00~17:20 Persistent Low-Level Viremia on Nucleos(t)ide Analogues in CHB Patients: Clinical Impact and Management Algorithms Room 1AB Chun-Jen Liu(National Taiwan Univ., Taiwan)
17:20~17:40 AI-Driven Strategies for Chronic Hepatitis B: From Prediction to Post-Cure Risk Stratification Room 1AB 허문행(서울의대)
07:30~08:00 Unmet Needs in the Clinical Practice of Viral Hepatitis Room 1C 정장한(한림의대)
13:30~13:50 Immunopathogenesis and Overlap Syndromes in Autoimmune Liver Diseases Room 1C 김자경(연세의대)
13:50~14:10 Hard-to-Treat Autoimmune Liver Diseases: Lessons from Clinical Cases Room 1C 이순규(가톨릭의대)
14:10~14:30 Treatment Optimization in Autoimmune Hepatitis: When First-Line Therapy Fails Room 1C Atsumasa Komori(Nagasaki Univ., Japan)
14:30~14:50 Beyond Ursodeoxycholic Acid: The Next Chapter in Primary Biliary Cholangitis Treatment Room 1C Yu Jun Wong(Duke-NUS Medical School, Singapore)
14:50~15:10 Emerging Evidence: Ongoing Prospective Trials in Cirrhosis from Korea Room 1C 강성희(고려의대)
15:10~15:30 LiverRCT: CHESS Ongoing Randomized Controlled Trials of Cirrhotic Portal Hypertension Room 1C Xiaolong Qi(Liver Health Consortium in China (CHESS), China)
15:30~15:50 Clinical Insights from the Korean Multicenter HVPG Cohort Room 1C 류담(순천향의대)
15:50~16:10 Vasomics: CHESS Emerging Technologies of Cirrhotic Portal Hypertension Room 1C Ling Yang(Southeast Univ., China)
16:20~16:40 Evaluation and Management of Abnormal Liver Function Tests in Clinical Practice Room 1C 송병근(성균관의대)
16:40~17:00 Assessing Tumor Response in HCC: RECIST and mRECIST Room 1C 박효정(울산의대)
17:00~17:20 Practical Approaches to Metabolic Dysfunction-Associated Steatohepatitis (MASH) Therapy and Complication Management Room 1C 김하일(한양의대)
17:20~17:40 How to Report Complications: CTCAE and SUSAR Room 1C 박태근(서울의대)
09:10~09:30 Controversies in Imaging-Based Diagnosis of HCC: Revisiting Major Features and Regional Differences Room 2AB 박효정(울산의대)
09:30~09:50 AI-Driven Prediction and Risk Stratification for HCC Surveillance Room 2AB 신현재(서울의대)
09:50~10:10 Biomarkers for HCC Diagnosis and Surveillance: Beyond AFP Room 2AB 이혜원(연세의대)
10:10~10:30 Chemoprevention in MASLD: Can We Reduce the Risk of HCC? Room 2AB 송정은(대구가톨릭의대)
12:40~13:40 KLCA General Meeting Room 2AB
13:40~14:40 2026 KLCA-NCC Practice Guidelines for Hepatocellular Carcinoma Room 2AB 김보현(국립암센터)
14:50~15:10 Evolving Landscape of Immunotherapy in HCC: Finding the Optimal Partner Room 2AB 신의철(KAIST)
15:10~15:30 Anti-VEGF as a Partner to PD-L1 Blockade Room 2AB Antonio D(King)
15:30~15:50 Dual Immune Blockade in HCC Room 2AB 김보현(국립암센터)
15:50~16:10 Panel Discussion: Choosing the Best Partner for Anti-PD-1/L1 Room 2AB
16:20~16:40 MASLD-HCC Carcinogenesis: Genetics and Metabolic Drivers Room 2AB 유수종(서울의대)
16:40~17:00 Immunity and Resistance in MASLD-HCC: Strategies for Immune Checkpoint Inhibitor Therapy Room 2AB Arndt Vogel(Univ. of Toronto, Canada)
17:00~17:20 Prognostic Imaging: Assessing Risk and Predicting Outcomes in MASLD-HCC Room 2AB 이선영(연세의대)
17:20~17:40 Tailoring Immunotherapy for MASLD-HCC: Challenges and Emerging Strategies Room 2AB Takahiro Kodama(Osaka Univ., Japan)
07:30~08:00 Clinical and Epidemiological Analysis of HEV Infection Based on the Nation-Wide Surveillance of Hepatitis E in Japan Room 2C Jong-Hon Kang(Teine Keijinkai Hospital, Japan)
08:00~08:20 MASLD Phenotypic Diversity: From Genetic Discovery to Precision Medicine Stratification Room 2C Stefano Romeo (Karolinska Institutet, Sweden)
08:20~08:40 Inflammation-Fibrosis Axis and Regulatory Mechanisms in MASH Room 2C 한용현(강원의대)
08:40~09:00 The Metabolic Triad in MASLD-MASH: Glucose, Lipid, and Amino Acid Dysregulation Room 2C Tatsuya Kanto(Japan Institute for Health Security, Japan)
09:10~09:30 Hepatic Stellate Cell Activation and Fibrosis Reversal Mechanisms Room 2C David A. Brenner(Sanford Burnham Prebys, USA)
09:30~09:50 Multi-Omics and Single-Cell Spatial Insights for HCC Target Discovery Room 2C 이정석(KAIST)
09:50~10:10 Senescent Hepatocytes as Tumor Seedbeds in MASH: Lessons from Single-Cell Maps Room 2C Michael Karin(Sanford Burnham Prebys, USA)
10:10~10:30 Multi-Modal Analysis of Human Stellate Cells Identifies Novel Therapeutic Targets for MASLD Room 2C 김현영(단국의대)
13:30~13:50 Principles of Cohort Study Design: From Question to Data Room 2C W. Ray Kim(Mayo Clinic, USA)
13:50~14:10 How to Conduct Successful Multinational Cohort Studies Room 2C 이정훈(서울의대)
14:10~14:30 From Statistical Associations to Causal Inference: The Role of Regression and Propensity Methods Room 2C 김세희(울산의대)
14:30~14:50 Applying Survival and Multivariable Analysis in Clinical Research: Interpreting the Results Room 2C 연동건(경희의대)
14:50~15:10 Target Trial Emulation in Hepatology Research Room 2C 김경아(성균관의대)
15:10~15:30 Application of Directed Acyclic Graphs (DAGs) and Mediation Analysis for Causal Inference Room 2C 정선재(연세의대)
15:30~15:50 Application of Vibe Coding in Liver Disease Research Room 2C 한지원(가톨릭의대)
15:50~16:10 Sensitivity Analysis Methodologies in Epidemiologic Research Room 2C 이혜성(강원의대)
16:20~16:40 Promotion of Precision Health Using Molecular and Genomic Biomarkers in Liver Diseases Room 2C Chien-Jen Chen(Genomics Research Center, Taiwan)
16:40~17:00 Microbiome-Metabolite Cross-Talk in Liver Diseases Room 2C 석기태(한림의대)
17:00~17:20 Genetic Causal Inference in Liver Diseases Using Mendelian Randomization Room 2C 정성원(울산의대)
09:10~09:30 Who, When, and Why: Selection Criteria and Timing for Liver Transplantation in HCC with Portal Vein Tumor Thrombosis Room 3 이재근
09:30~09:50 Downstaging to Transplant: Converting the Unresectable to the Transplantable Room 3 Prashant Bhangui (Medanta Institute, India)
09:50~10:10 Operative Strategy and Technical Pitfalls in Liver Transplantation for HCC with Portal Vein Tumor Thrombosis Room 3 문덕복(울산의대)
10:10~10:30 Post-Transplant Care and Recurrence Management: Adjuvant and Salvage Strategies Room 3 이광웅(서울의대)
11:40~12:00 Analysis of Symptoms in Liver Transplant Recipients and Living Donors Room 3 최지연(연세의대)
12:00~12:20 Experience and Adaptation after Liver Transplantation: A Qualitative Research Review Room 3 손선영(강남세브란스병원)
12:20~12:40 Depressive Symptoms and Self-Care in Liver Transplant Recipients Room 3 정서하(연세의대)
13:30~13:50 Beyond Body Mass Index (BMI): Clinical Utility of InBody and Bioimpedance in Liver Transplant Evaluation Room 3 서석원(중앙의대)
13:50~14:10 Prognostic Significance of Sarcopenia and Visceral Fat in Liver Transplant Recipients Room 3 Toshimi Kaido(St. Luke)
14:10~14:30 Extracellular Water Imbalance and Fluid Overload: Impact on Early Graft Function and Complications Room 3 김민섭(서울의대)
14:30~14:50 Significance of Body Composition in Liver Transplantation Room 3 오승영(서울의대)
14:50~15:10 The MASLD Era and Its Impact on the Liver Donor Pool Room 3 정보현(인제의대)
15:10~15:30 Outcomes and Risk Factors of Liver Transplantation Using Steatotic Grafts for HCC Room 3 Fengqiang Gao(Zhejiang Univ., China)
15:30~15:50 Recurrent Steatosis in Living Donors after Pre-Donation Weight Reduction and Subsequent Weight Regain Room 3 윤영인(울산의대)
15:50~16:10 Recurrent and de novo MASLD after Liver Transplantation Room 3 김태석(계명의대)
07:30~08:00 Hepatorenal Syndrome in Patients with Hepatic Hydrothorax Room 4A 은혁수(충남의대)
13:30~13:55 National Viral Hepatitis Elimination Strategy Room 4A 이형민(질병관리청)
13:55~14:20 Reimbursement Principles and History of Viral Hepatitis Treatment Room 4A 곽애란(HIRA)
14:20~14:45 Unmet Need of Clinical Practice in Chronic Viral Hepatitis Room 4A 김순선(아주의대)
07:30~08:00 Clinical Application of Non-Invasive Modalities for Fibrosis Assessment in MASLD Room 4B 장병국(계명의대)
07:30~08:00 Regionally Led Project for HCV Micro-Elimination: Jindo-gun Room 4C 신민호(충남의대)